Fagerstrom K - Search Results

1

Estimating the harms of nicotine-containing products using the MCDA approach.

Nutt DJ, Phillips LD, Balfour D, Curran HV, Dockrell M, Foulds J, Fagerstrom K, Letlape K, Milton A, Polosa R, Ramsey J, Sweanor D. Nutt DJ, et al. Among authors: fagerstrom k. Eur Addict Res. 2014;20(5):218-25. doi: 10.1159/000360220. Epub 2014 Apr 3. Eur Addict Res. 2014. PMID: 24714502 Free article.

2

E-cigarettes are less harmful than smoking.

Nutt DJ, Phillips LD, Balfour D, Curran HV, Dockrell M, Foulds J, Fagerstrom K, Letlape K, Polosa R, Ramsey J, Sweanor D. Nutt DJ, et al. Among authors: fagerstrom k. Lancet. 2016 Mar 19;387(10024):1160-2. doi: 10.1016/S0140-6736(15)00253-6. Lancet. 2016. PMID: 27025332 Free article. No abstract available.

3

Pharmacology of nicotine and its therapeutic use in smoking cessation and neurodegenerative disorders.

Balfour DJ, Fagerström KO. Balfour DJ, et al. Among authors: fagerstrom ko. Pharmacol Ther. 1996;72(1):51-81. doi: 10.1016/s0163-7258(96)00099-x. Pharmacol Ther. 1996. PMID: 8981571 Review.

4

Diagnosis and treatment of nicotine dependence with emphasis on nicotine replacement therapy. A status report.

Balfour D, Benowitz N, Fagerström K, Kunze M, Keil U. Balfour D, et al. Among authors: fagerstrom k. Eur Heart J. 2000 Mar;21(6):438-45. doi: 10.1053/euhj.1999.1949. Eur Heart J. 2000. PMID: 10681484 Review.

5

Neuropharmacology and potential efficacy of new treatments for tobacco dependence.

Fagerström K, Balfour DJ. Fagerström K, et al. Expert Opin Investig Drugs. 2006 Feb;15(2):107-16. doi: 10.1517/13543784.15.2.107. Expert Opin Investig Drugs. 2006. PMID: 16433591 Review.

6

Effect of smokeless tobacco (snus) on smoking and public health in Sweden.

Foulds J, Ramstrom L, Burke M, Fagerström K. Foulds J, et al. Among authors: fagerstrom k. Tob Control. 2003 Dec;12(4):349-59. doi: 10.1136/tc.12.4.349. Tob Control. 2003. PMID: 14660766 Free PMC article. Review.

7

The Fagerström Test for Nicotine Dependence as a predictor of smoking abstinence: a pooled analysis of varenicline clinical trial data.

Fagerström K, Russ C, Yu CR, Yunis C, Foulds J. Fagerström K, et al. Nicotine Tob Res. 2012 Dec;14(12):1467-73. doi: 10.1093/ntr/nts018. Epub 2012 Mar 30. Nicotine Tob Res. 2012. PMID: 22467778 Clinical Trial.

8

FCTC background report on smokeless tobacco is incompatible with WHO scientific reports.

Borland R, Fagerström K, Foulds J, McNeill A, Ramström L. Borland R, et al. Among authors: fagerstrom k. Addiction. 2011 Jan;106(1):225-7. doi: 10.1111/j.1360-0443.2010.03250.x. Epub 2010 Nov 3. Addiction. 2011. PMID: 21050296 No abstract available.

9

Tobacco harm reduction: the need for new products that can compete with cigarettes.

Fagerström KO, Bridgman K. Fagerström KO, et al. Addict Behav. 2014 Mar;39(3):507-11. doi: 10.1016/j.addbeh.2013.11.002. Epub 2013 Nov 10. Addict Behav. 2014. PMID: 24290207 Free article. Review.

10

European Union policy on smokeless tobacco: a statement in favour of evidence based regulation for public health.

Bates C, Fagerström K, Jarvis MJ, Kunze M, McNeill A, Ramström L. Bates C, et al. Among authors: fagerstrom k. Tob Control. 2003 Dec;12(4):360-7. doi: 10.1136/tc.12.4.360. Tob Control. 2003. PMID: 14660767 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

121 results

Search Page